• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

coronavirus

Overcoming vaccine delivery device design’s top challenges

August 30, 2021 By Sean Whooley

Pfizer COVID-19 vaccine

Vaccine delivery has long been a hot topic and only got hotter in the ongoing push to vaccinate against COVID-19 around the world. Most would probably associate vaccines with the standard “jab” injection with a syringe. Over the past year and more, companies have touted ideas for other avenues. Inovio has a “smart” delivery device […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, Intravacc, Pfizer-BioNTech, vaccines

Three companies to collaborate on potential inhaled COVID-19 treatment

August 26, 2021 By Sean Whooley

SignalRx Crystec Adya

Signal Rx Pharmaceuticals, Crystec and ADYA are working on a dry powder drug formulation for potentially treating COVID-19-related illness. The three companies’ collaboration for the dry powder formulation of SF2523 covers the treatment of pulmonary fibrosis, lung cancer and illnesses related to SARS-CoV-2, the virus causing COVID-19. SignalRx’s SF2523 is a novel, small-molecule, dual PI3K-BRD4 […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: ADYA, coronavirus, COVID-19, Crystec, SignalRx

Vaxart stock soars after FDA approves IND application for oral COVID-19 vaccine tablet

August 2, 2021 By Sean Whooley

Vaxart

Vaxart (NSDQ:VXRT) announced today that the FDA cleared the investigational new drug (IND) application for its oral COVID-19 vaccine. Upon news of the IND application approval for the S-only protein construct-based vaccine candidate, shares of VXRT were up 16.1% at $8.35 in early-morning trading today. South San Francisco-based Vaxart’s S+N oral tablet SARS-CoV-2 vaccine candidate […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: coronavirus, COVID-19, FDA, Vaxart

Teva dips before hours on Q2 revenue miss, lowered guidance

July 28, 2021 By Sean Whooley

Teva

Teva Pharmaceuticals (NYSE:TEVA) shares took a hit this morning on second-quarter revenues that missed the consensus forecast. The Tel Aviv, Israel-based company posted profits of $207 million, or 19¢ per share, on sales of $3.9 billion for the three months ended June 30, 2021, for a 47.9% bottom-line gain on sales growth of 1%. Adjusted […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: coronavirus, COVID-19, Teva, Teva Pharmaceuticals

PharmaJet begins enrollment for needle-free COVID-19 vaccine trial

June 30, 2021 By Sean Whooley

PharmaJet

PharmaJet announced today that it began enrollment for a Phase 1 clinical trial for its needle-free COVID-19 vaccine in Australia. Golden, Colo.-based PharmaJet’s needle-free injection systems will be studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. According to a news release, PharmaJet’s system was chosen […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

BD surpasses 2 billion orders for COVID-19 vaccine injection devices

June 8, 2021 By Sean Whooley

BD_2B_vaccination_devices

BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices. The order total encompasses commitments to governments all over the globe, including the U.S., […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD, coronavirus, COVID-19, COVID-19 vaccine

NRx Pharmaceuticals touts Zyesami results, seeks EUA for treating COVID-19

June 1, 2021 By Sean Whooley

NRx NeuroRx_Logo

NRx Pharmaceuticals (NSDQ:NRXP) announced that it applied for FDA emergency use authorization based on a study of its Zyesami therapeutic. Radnor, Pa.-based NRx Pharmaceuticals, formerly NeuroRx, just last week completed a merger with SPAC Big Rock Partners Acquisition Corp. and went public, changing its name in the process. The company develops Zyesami, a synthetic form […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: coronavirus, COVID-19, NeuroRx, NRx

BD to build $200M facility in Spain for pre-filled drug delivery device manufacturing

May 18, 2021 By Sean Whooley

BD

BD (NYSE:BDX) announced today that it will build a more than $200 million drug delivery device manufacturing facility in Spain. The approximately $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, is expected to create up to 600 jobs by 2030, according to a news release. In December, BD announced its plan to invest […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD, Becton Dickinson, coronavirus, COVID-19, COVID-19 vaccine

Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine

April 7, 2021 By Sean Whooley

Intravacc

Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day one and […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials Tagged With: coronavirus, COVID-19, COVID-19 vaccine, Intravacc

Diomics, Bonne Santé Group enter strategic alliance

March 29, 2021 By Sean Whooley

Diomics Bonne Sante

Diomics and Bonne Santé Group announced today that they entered into a strategic alliance to develop a line of Diocare products. San Diego-based Diomics and Miami-based Bonne Santé Group, which operated through its Bonne Santé Natural Manufacturing division, entered the agreement in an effor tto develop, launch and distribute the Diocare products formulated to address […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bonne Sante Group, coronavirus, COVID-19, Diomics

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS